|Bid||357.63 x 1000|
|Ask||357.79 x 800|
|Day's Range||356.37 - 366.51|
|52 Week Range||226.02 - 373.90|
|Beta (3Y Monthly)||0.96|
|PE Ratio (TTM)||37.79|
|Earnings Date||Feb 19, 2020 - Feb 24, 2020|
|Forward Dividend & Yield||1.36 (0.39%)|
|1y Target Est||402.18|
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat […]
WAYNE, Pa., Nov. 21, 2019 -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 31st Annual Piper Jaffray Healthcare Conference at.
WAYNE, Pa., Nov. 11, 2019 -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, will showcase its Interventional product portfolio including.
WAYNE, Pa., Nov. 04, 2019 -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Stephens Nashville 2019 Investment Conference at.
When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...
We are encouraged by Teleflex's (TFX) robust improvement in Q3 revenues on balanced growth across majority of segments and all geographies.
Teleflex (TFX) delivered earnings and revenue surprises of 8.00% and 0.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
WAYNE, Pa., Oct. 31, 2019 -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per.
Third Quarter Revenues from Continuing Operations of $648.3 million, up 6.3% versus the Prior Year Period; up 8.0% on a Constant Currency Basis Third Quarter GAAP Diluted EPS.
Earnings and revenues for the Medical Instruments sector in the third quarter are likely to have declined sequentially. Read to know how a few companies from the sector might have fared in the period.
Growth investors are constantly looking for the next massive gainer. We mean the stocks that not only have a proven track record for growth but also exhibit strong long-term growth prospects that could yield high rewards in the years to come.While it’s often tempting to turn to more mainstream names like Apple, these better-known stocks don’t always offer the most upside from the current share price. In this case, stocks that have slipped away from investors' radars can represent more compelling investments as their biggest gains could still be on the way.That being said, finding these under-the-radar names that are poised to skyrocket can seem like a daunting task to even the most seasoned investors. Luckily, TipRanks’ Smart Score tool makes it a little easier. Using the tool, we were able to pinpoint 3 lesser-known stocks primed to take off.Teleflex (TFX)Teleflex develops and manufactures single-use medical devices such as products used for anesthesia, fluid management as well as hand-held instruments. While experiencing a rocky last few months, several analysts believe TFX is well positioned to deliver high returns.Part of the medical device company’s appeal lies with its UroLift product. The system, which is a minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), has been approved by the FDA and has been used to treat over 100,000 men globally. With TFX placing the available market opportunity in the U.S. at $6 billion due to the fact that 1.5 million men with BPH have abandoned treatment, UroLift is expected to continue to fuel significant revenue.Additionally, its new MANTA vascular closure device looks especially promising. With the full launch of MANTA slated for 2020, Jeffries analyst Raj Denhoy believes TFX has a “best-in-class reported and organic top-line growth profile relative to peers”. He added, “With TFX now positioned as one of the better positioned mid-cap hospital supply providers, the company is now increasingly attractive to larger diversified medtech peers."As a result, the five-star analyst reiterated a Buy rating and $415 price target on TFX stock. Based on Denhoy's price target, shares could surge 29% over the next twelve months. (To watch Denhoy’s track record, click here)Similarly, the rest of the Street takes a bullish approach when it comes to TFX. 6 Buy ratings and 1 Hold give the stock a ‘Strong Buy’ analyst consensus. Its $397 average price target suggests 24% upside potential. (See Teleflex stock analysis on TipRanks)DuPont de Nemours (DD)It’s no question that the chemical company has received its fair share of negative attention in recent years. Nonetheless, DuPont shares could get a lift thanks to its focus on active portfolio management.Management believes synergies resulting from recent M&A activity could drive substantial gains in terms of revenue. On October 3, DD announced that it had agreed to acquire the Memcor business from Evoqua Water Technologies Corporation. As a result of the deal, Dupont will get access to Evoqua’s ultrafiltration and membrane biofiltration technologies. This acquisition comes on the heels of an earlier agreement with BASF to acquire the ultrafiltration membrane segment of the business.Not to mention the company should see cash flow improve following the sale of its Compound Semiconductor Solutions business.Bearing this in mind, Morgan Stanley analyst Vincent Andrews sees DD’s potential 12-month gain falling at 28%, as he reiterates an Overweight rating and $85 price target. (To watch Andrews’ track record, click here)“We remain of the view that: 1) A ~$100 per share bull case exists should the company achieve max strategic value creation with its four generally unrelated segments; 2) The current share price does not price in any strategic value creation, but rather a typical conglomerate discount,” Andrews noted.Wall Street anchor a bullish perspective on the chemicals maker, as TipRanks analytics showcase DD as a Moderate Buy. Based on 12 analysts polled by TipRanks in the last 3 months, 8 rate DD a "buy," while 4 say "hold." The 12-month average price target stands at $80.82, marking a nearly 20% upside from where the stock is currently trading. (See DuPont stock analysis on TipRanks)Corteva (CTVA)Originally the agricultural component of DowDuPont, Corteva is now a separate company specializing in agricultural chemicals and seeds. With shares dipping 8% in the last month, Deutsche Bank’s David Begleiter argues that the drop represents a unique buying opportunity.The company has recently added a new bundling program called Corteva Cash, with the product already proving to be successful. The bundling program gives seed purchasers a cash credit that can be used to buy pesticides from Corteva. As a result, there has been an uptick in purchases of CTVA pesticides from farmers.In addition to Corteva Cash, the company has placed a significant focus on improving its productivity levels. CTVA recently announced the launch of its “Execute to Win” productivity program to fuel $500 million of EBITDA over the next five years. A new ERP platform is also being put into place in order to address excess costs from its three disparate IT systems including DuPont Crop Protection, Pioneer and Dow Agrosciences, as well as simplify business operations.All of this lends itself to Begleiter’s conclusion that CTVA’s 2x EBITDA discount to FMC Corporation is “unwarranted”. “With double-digit EBITDA growth over the next 3-4 years largely in its own control (due to its substantial cost synergies and productivity initiatives) and valuation compelling versus its closest peer, we reiterate our Buy rating,” he commented. Along with his Buy rating, the five-star analyst set a $35 price target, indicating 37% upside potential. (To watch Begleiter’s track record, click here)Overall, the agricultural chemical maker has had 3 bullish analysts in its corner over the last three months, along with 2 neutral analysts. Importantly, the 12-month average price target of $33,40 showcases 25% in upside potential for the stock.
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WAYNE, Pa., Oct. 17, 2019 -- Teleflex Incorporated (NYSE: TFX) announced today that financial results for the third quarter 2019 will be released before market open on.
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Teleflex Inc. announced Monday a voluntary recall of its Babi.Plus water pressure relief manifold following a notice received from manufacturer GaleMed Corp. after reports that the bubble continuous positive airway pressure (BCPAP) pressure system would not hold pressure. The company said the recalled products were distributed from October 2018 to May 2019. GaleMed said it received two reports of device malfunction but no reports of injuries. The Food and Drug Administration is classified the recall as a Class 1 recall, which is defined as "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death." Teleflex's stock, which was still inactive in premarket trading, has rallied 27.7% year to date, while the S&P 500 has gained 17.8%.
Teleflex Incorporated (TFX), announced a recall June 14th, 2019 of certain lots of the GaleMed (third party manufacturer) Babi.Plus® 12.5 cm H2O Pressure Relief Manifold. Teleflex receives the product from the manufacturer GaleMed Corporation and is one of its distributors for this product within the United States.
Teleflex Incorporated (TFX), a leading global provider of medical technologies, today announced the tenth anniversary of its industry-leading GuideLiner® Catheter. Released in November 2009, the GuideLiner® Catheter revolutionized the concept of guide extension in the medical device industry. Since that time, the company has sold more than 1 million GuideLiner® Catheters—from three product generations—across 62 countries, including more than 550,000 units in North America alone.
Teleflex Incorporated (TFX) today announced the publication of an article showcasing the effectiveness and overall benefits of the minimally invasive UroLift® System treatment for patients with benign prostatic hyperplasia (BPH). The article, DeMISTifying less-invasive solutions for BPH, reviews the objectives of using minimally invasive surgical technologies (MIST) to treat BPH, and recommends useful metrics to measure the success of these treatments, including the UroLift System. The article, published in Urology Times, is authored by Steven Kaplan, M.D., professor of Urology, Icahn School of Medicine at Mount Sinai and director of the Men’s Health Program at Mount Sinai Health System, New York.
WAYNE, Pa., Sept. 13, 2019 -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, will focus on its Arrow® EZ-IO® Intraosseous Access System.
Executive Vice President & CFO of Teleflex Inc (30-Year Financial, Insider Trades) Thomas E Powell (insider trades) sold 7,500 shares of TFX on 09/06/2019 at an average price of $355.52 a share. Continue reading...